Tazobactam → 2-[(Z)-[2-[[(6R,7R)-3-[[5-amino-4-(2-aminoethylcarbamoylamino)-1-methylpyrazol-2-ium-2-yl]methyl]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-1-(5-amino-1,2,4-thiadiazol-3-yl)-2-oxoethylidene]amino]oxy-2-methylpropanoate

HRID 1399506노트

반응식

HRID 1399506 반응식
C[C@@]1(CN2N=NC=C2)S(=O)(=O)[C@@H]2CC(=O)N2[C@H]1C(O)=O.[CH3:21][C:22]([O:27]/[N:28]=[C:29](\[C:36]([NH:38][C@@H:39]1[C:42](=[O:43])[N:41]2[C:44]([C:63]([OH:65])=[O:64])=[C:45]([CH2:48][N+:49]3[N:53]([CH3:54])[C:52]([NH2:55])=[C:51]([NH:56][C:57]([NH:59][CH2:60][CH2:61][NH2:62])=[O:58])[CH:50]=3)[CH2:46][S:47][C@H:40]12)=[O:37])/[C:30]1[N:31]=[C:32]([NH2:35])[S:33][N:34]=1)([C:24]([O-:26])=[O:25])[CH3:23].OS(O)(=O)=O>>[CH3:23][C:22]([O:27]/[N:28]=[C:29](\[C:36]([NH:38][C@@H:39]1[C:42](=[O:43])[N:41]2[C:44]([C:63]([OH:65])=[O:64])=[C:45]([CH2:48][N+:49]3[N:53]([CH3:54])[C:52]([NH2:55])=[C:51]([NH:56][C:57]([NH:59][CH2:60][CH2:61][NH2:62])=[O:58])[CH:50]=3)[CH2:46][S:47][C@H:40]12)=[O:37])/[C:30]1[N:31]=[C:32]([NH2:35])[S:33][N:34]=1)([C:24]([O-:26])=[O:25])[CH3:21]

참가 물질

3

반응물 2

HCID 123630TazobactamHCID 49863419HCID 49863419, 화합물

생성물 1

HCID 714579552-[(Z)-[2-[[(6R,7R)-3-[[5-amino-4-(2-aminoethylcarbamoylamino)-1-methylpyrazol-2-ium-2-yl]methyl]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-1-(5-amino-1,2,4-thiadiazol-3-yl)-2-oxoethylidene]amino]oxy-2-methylpropanoate

실험 절차

lyophilizing a first aqueous solution in the absence of tazobactam, the first aqueous solution comprising ceftolozane sulfate at a pH of 5-7 (e.g, 6-7) prior to lyophilization to obtain a first lyophilized ceftolozane composition,

출처 및 근거

ORD 기록
ord-f5d607e3a7ad474a8f881766bb55d809
출처 데이터셋
uspto-grants-2014_12
특허 번호
US08906898B1

반응 노트

불러오는 중…